Home > Boards > US Listed > Biotechs > ImmunoGen, Inc. (IMGN)

BREAKING NEWS: $IMGN ImmunoGen Announces FDA Breakthrough Therapy

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
whytestocks Member Profile
 
Followed By 115
Posts 15,034
Boards Moderated 1
Alias Born 06/04/18
160x600 placeholder
ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2021 Operating Results Business Wire - 10/14/2021 4:01:00 PM
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire - 10/1/2021 4:30:00 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 9/23/2021 4:34:44 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/23/2021 4:26:10 PM
ImmunoGen Appoints Helen M. Thackray, MD to its Board of Directors Business Wire - 9/22/2021 4:01:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/3/2021 4:07:48 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 8/12/2021 10:12:13 AM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 8/9/2021 4:11:37 PM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 8/9/2021 4:11:11 PM
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire - 8/2/2021 4:30:00 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 7/30/2021 5:13:16 PM
ImmunoGen posts wider Q2 net loss as R&D expenses ramp Seeking Alpha - 7/30/2021 7:50:08 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/30/2021 6:37:33 AM
ImmunoGen EPS beats by $0.03, misses on revenue Seeking Alpha - 7/30/2021 6:36:14 AM
ImmunoGen Reports Recent Progress and Second Quarter 2021 Financial Results Business Wire - 7/30/2021 6:30:00 AM
ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2021 Operating Results Business Wire - 7/15/2021 4:01:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/2/2021 4:25:21 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/2/2021 4:23:28 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/2/2021 4:23:10 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/2/2021 4:21:57 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/2/2021 4:21:41 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/2/2021 4:20:28 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/2/2021 4:19:54 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/2/2021 4:18:36 PM
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire - 7/1/2021 4:30:00 PM
whytestocks   Monday, 10/05/20 09:15:46 PM
Re: None
Post # of 743 
BREAKING NEWS: $IMGN ImmunoGen Announces FDA Breakthrough Therapy Designation for IMGN632 in Relapsed or Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm

ImmunoGen, Inc. , (Nasdaq: IMGN) a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for IMGN632 for the treatment of patients wi...

Got this from IMGN - ImmunoGen Announces FDA Breakthrough Therapy Designation for IMGN632 in Relapsed or Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences